《Rheumatology International》：Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple Sclerosis-like syndrome: a systematic review 【字体： 大 中 小 】 时间：2025年06月04日 ...

Researchers have found in a recent analysis reveals IL-17 inhibitors significantly increase the risk of Candida infections ...

两篇Cell齐发：抗感染的细胞因子IL-17还作用于大脑，引发焦虑或促进社交. 来源：生物世界 2025-04-11 11:13. 这两项研究共同表明，免疫系统，甚至单个 ...

来自巴塞罗那生物医学研究所(IRB Barcelona)与国家基因组分析中心(CNAG)合作的一组科学家发现，IL-17蛋白在皮肤老化中起着核心作用。这项研究由巴塞罗那IRB的Guiomar Solanas博士、Salvador Aznar Benitah博士和CNAG的Holger Heyn博士领导，强调了Il -17介导的衰老过程到炎症状态。

本研究是首个银屑病领域在il-17单抗应答不佳人群中开展转药治疗的随机、双盲、活性对照的iii期临床研究，在il-17单抗继续治疗对照下，证明匹康奇 ...

通过对修复相关的淋巴细胞进行无偏见的分析，这些作者发现了17型淋巴细胞的异质性群体的富集。缺少RORγt+细胞的纯合子Rorgt-EGFP小鼠（下称GFI-KI小 ...

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis ...

IL-17A, commonly referred to as IL-17, is the founding member of the IL-17 family, which consists of six ligands, A–F. IL-17F shares 50% sequence homology with IL-17A and has similar but less ...

Aging：揭示促炎性细胞因子IL-17在骨关节炎发病机制中的关键作用. 来源：生物谷原创 2024-02-24 10:56. 这项研究中，研究人员利用来自健康供体和骨关节 ...

Interleukin-17 and IL-23 inhibitors do not increase the risk for tuberculosis reactivation among patients with psoriatic disease who have a latent tuberculosis infection, according to a ...

礼来IL-23单抗头对头击败乌司奴单抗。 2024年10月14日，礼来更新了旗下IL-23单抗mirikizumab（米吉珠单抗）治疗中重度克罗恩病（CD）患者的三期VIVID-1 ...

Interleukin-17 (IL-17) inhibitors demonstrated faster psoriasis (PsO) clearance than Interleukin-23 (IL-23) inhibitors. However, IL-23 inhibitors were often favored due to their safety profile and ...